TC
Tejas Champaklal Shah
About Tejas Champaklal Shah
Data last updated:
Tejas Champaklal Shah is a Director at Abil Chempharma Private Limited (since 2012), Director at Daivat Lifesciences Private Limited (since 2023) and Director at Dabilife Pharma Private Limited (since 2021). The companies operate in Pharma and Life Sciences. The 3 current companies with reported revenue have a combined latest revenue of ₹901 Cr; the largest is Abil Chempharma Private Limited at ₹795 Cr (FY 2025). Earlier, Tejas Champaklal Shah was a Designated Partner at Hexamed Life Sciences Llp (2019) and Director at P R Pharma Source Private Limited (2007–2014).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Abil Chempharma Private Limited U51397MH2002PTC137264 | Director | 01 Dec 2012 | 2002 | ₹795 Cr (FY 2025) | Active |
| Daivat Lifesciences Private Limited U51909MH2021PTC359283 | Director | 04 Aug 2023 | 2021 | ₹105 Cr (FY 2025) | Active |
| Dabilife Pharma Private Limited U51909MH2021PTC359801 | Director | 03 May 2021 | 2021 | ₹38.4 Lakh (FY 2025) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Hexamed Life Sciences Llp AAO-2880 | Designated Partner | 15 Feb 2019 | 2019 | Active | |
 P R Pharma Source Private Limited U52311MH2007PTC171721 | Director | 16 Jun 2007 | 2007 | ₹56.27 Cr (FY 2025) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Tejas Champaklal Shah
| Name | DIN | Company | Designation |
|---|---|---|---|
| Jayesh Ajit Paurana | 11651706 | Abil Chempharma Private Limited | Additional Director |
| Sanket Jatin Gandhi | 10282271 | Abil Chempharma Private Limited | Director |
| Manan Mukesh Parikh | 08524288 | Daivat Lifesciences Private Limited | Director |
| Tejas Ramesh Zaveri | 10499648 | Dabilife Pharma Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Tejas Champaklal Shah
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tejas Champaklal Shah
Tejas Champaklal Shah currently holds 3 directorships: Abil Chempharma Private Limited (Director, since 01 Dec 2012, revenue ₹795 Cr (FY 2025)); Daivat Lifesciences Private Limited (Director, since 04 Aug 2023, revenue ₹105 Cr (FY 2025)); Dabilife Pharma Private Limited (Director, since 03 May 2021, revenue ₹38.4 Lakh (FY 2025)).
Tejas Champaklal Shah was first appointed on 16 Jun 2007 as Director at P R Pharma Source Private Limited. The most recent appointment on record is 04 Aug 2023 at Daivat Lifesciences Private Limited.
The 3 current companies of Tejas Champaklal Shah that report revenue have a combined latest revenue of ₹901 Cr: Abil Chempharma Private Limited ₹795 Cr (FY 2025); Daivat Lifesciences Private Limited ₹105 Cr (FY 2025); Dabilife Pharma Private Limited ₹38.4 Lakh (FY 2025).
Tejas Champaklal Shah held 2 earlier board appointments: Hexamed Life Sciences Llp (Designated Partner, 15 Feb 2019 to 28 Jun 2019); P R Pharma Source Private Limited (Director, 16 Jun 2007 to 28 Feb 2014).
The current boards of Tejas Champaklal Shah's companies include Jayesh Ajit Paurana (Abil Chempharma Private Limited), Sanket Jatin Gandhi (Abil Chempharma Private Limited), Manan Mukesh Parikh (Daivat Lifesciences Private Limited), Tejas Ramesh Zaveri (Dabilife Pharma Private Limited).